/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Genenta Science SPA

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.9 -0.0207(-2.07%) GNTA at 04 Dec 2025 04:33 PM Biotechnology
Lowest Today 1.8
Highest Today 1.93
Today’s Open 1.93
Prev. Close 1.93
52 Week High 6.20
52 Week Low 1.35
Day’s Range: Low 1.8 High 1.93
52-Week Range: Low 1.35 High 6.20
1 day return -
1 Week return -4.95
1 month return -18.64
3 month return -46.21
6 month return -56.36
1 year return -61.98
3 year return -65.95
5 year return -
10 year return -

Institutional Holdings

Eurizon Azioni Internazionali 1.97

Allianz SE 1.28

AlTi Global Inc 1.10

Kairos Intl SICAV Italia P 1.09

Mediolanum Flessibile Futuro Italia LA 1.08

Investitori Flessibile 0.63

Kairos Intl SICAV Made in Italy Y 0.57

Algebris Investment Management (UK) LLP 0.55

Anthilia Small Cap Italia A 0.48

Investitori America 0.46

LUX IM Global Medtech HX 0.33

Planetarium Anthilia Red B EUR 0.21

Investitori Longevity A 0.19

Lemanik SICAV High Growth Cap Retail EUR 0.11

Kairos Intl SICAV Patriot P 0.11

Lemanik SICAV Eurp Spec Sits Cap Ret EUR 0.08

Kairos Intl SICAV Opports L/S P 0.07

Morgan Stanley - Brokerage Accounts 0.01

Citadel Advisors Llc 0.00

UBS Group AG 0.00

Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 45.22 M

PB Ratio 3.3682

PE Ratio 0.0

Enterprise Value 35.60 M

Total Assets 14.82 M

Volume 72329

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:-41582 -0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-11406747 -11.4M, FY22:-3624844 -3.6M, FY21:-5560705 -5.6M, FY20:-5605734 -5.6M, FY19:-4607275 -4.6M

Quarterly Revenue Q3/2025:null 0.0M, Q2/2024:null 0.0M, Q4/2023:null 0.0M, Q3/2023:null 0.0M, Q2/2023:null 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2024:null 0.0M, Q4/2023:-20883 -0.0M, Q3/2023:null 0.0M, Q2/2023:null 0.0M

Quarterly Net worth Q3/2025:-3826585 -3.8M, Q2/2024:-4038506 -4.0M, Q4/2023:-4788396 -4.8M, Q3/2023:-2443 -0.0M, Q2/2023:null 0.0M

Fund house & investment objective

Company Information Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Organisation Biotechnology

Employees 13

Industry Biotechnology

CEO Mr. Pierluigi Paracchi

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow